Spain Somatic Genetic Testing Market Size & Outlook, 2026-2034

Spain Somatic Genetic Testing Market Insights

As highlighted in Deep Market Insights analysis, the Spain Somatic Genetic Testing Market, worth USD 153.59 Million in 2025, is forecasted to achieve USD 679.3 Million by 2034.
The Spain market is anticipated to grow at a CAGR of 17.79% during the period 2026–2034.
By 2025, Tumor profiling tests represented the largest share of the By Test Type market size.
Carrier screening is expected to remain the key growth driver within By Test Type, registering the fastest CAGR during the forecast period.

As of 2025, Spain held 2.9% of the global Somatic Genetic Testing Market size.
By 2034, United States is anticipated to capture the largest share of the global Somatic Genetic Testing Market.
In Europe, Germany is expected to lead the regional Somatic Genetic Testing Market size by 2034.
Italy will remain the fastest-growing market in Europe, reaching USD 923.1 Million by 2034.

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 153.59 Million
Market Size In 2034	USD 679.3 Million
Largest segment	Tumor profiling tests
Units	Revenue in USD Million
CAGR	17.79% (2026-2034)
Segmnetation Covered
By Test Type	Tumor profiling tests Carrier screening Predictive genetic tests Diagnostic genetic tests
By Technology	Next-generation sequencing PCR-based testing Microarray testing Sanger sequencing
By Application	Oncology Rare diseases Prenatal testing Personalized medicine
By End User	Hospitals Diagnostic laboratories Research institutes Clinics
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

By Test Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Tumor profiling tests	XX.x	XX.x	XX.x	67.9	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Carrier screening	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Predictive genetic tests	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic genetic tests	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Technology	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Next-generation sequencing	XX.x	XX.x	XX.x	62.65	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
PCR-based testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Microarray testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Sanger sequencing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By Application	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oncology	XX.x	XX.x	XX.x	66.67	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Rare diseases	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prenatal testing	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Personalized medicine	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: DMI Analysis Company Publications, Primary Interviews.

By End User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	69.28	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Diagnostic laboratories	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research institutes	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x